Search Page

1

Cite

Share

Nicotinic acid: clinical considerations.

Kei A, Elisaf MS. Kei A, et al. Expert Opin Drug Saf. 2012 Jul;11(4):551-64. doi: 10.1517/14740338.2012.682981. Epub 2012 May 7. Expert Opin Drug Saf. 2012. PMID: 22564238 Review.

Cite

Share

2

Cite

Share

Emerging drugs for hyperlipidaemia: an update.

Florentin M, Kostapanos MS, Kei A, Elisaf MS. Florentin M, et al. Among authors: kei a. Expert Opin Emerg Drugs. 2014 Dec;19(4):471-88. doi: 10.1517/14728214.2014.976553. Epub 2014 Oct 30. Expert Opin Emerg Drugs. 2014. PMID: 25356785 Review.

Cite

Share

3

Cite

Share

The current role of thiazolidinediones in diabetes management.

Rizos CV, Kei A, Elisaf MS. Rizos CV, et al. Among authors: kei a. Arch Toxicol. 2016 Aug;90(8):1861-81. doi: 10.1007/s00204-016-1737-4. Epub 2016 May 10. Arch Toxicol. 2016. PMID: 27165418 Review.

Cite

Share

4

Cite

Share

Uric acid and cardiovascular risk: What genes can say.

Kei A, Koutsouka F, Makri A, Elisaf M. Kei A, et al. Int J Clin Pract. 2018 Jan;72(1). doi: 10.1111/ijcp.13048. Epub 2017 Dec 18. Int J Clin Pract. 2018. PMID: 29250870 Review.

Cite

Share

5

Cite

Share

Review: Antiplatelet drugs: what comes next?

Kei AA, Florentin M, Mikhailidis DP, Elisaf MS, Liberopoulos EN. Kei AA, et al. Clin Appl Thromb Hemost. 2011 Feb;17(1):9-26. doi: 10.1177/1076029610385222. Epub 2010 Nov 15. Clin Appl Thromb Hemost. 2011. PMID: 21078606 Free article. Review.

Cite

Share

6

Cite

Share

Electrolyte and acid-base disorders in inflammatory bowel disease.

Barkas F, Liberopoulos E, Kei A, Elisaf M. Barkas F, et al. Among authors: kei a. Ann Gastroenterol. 2013;26(1):23-28. Ann Gastroenterol. 2013. PMID: 24714322 Free PMC article. Review.

Cite

Share

7

Cite

Share

The safety of ezetimibe and simvastatin combination for the treatment of hypercholesterolemia.

Kei AA, Filippatos TD, Elisaf MS. Kei AA, et al. Expert Opin Drug Saf. 2016;15(4):559-69. doi: 10.1517/14740338.2016.1157164. Epub 2016 Mar 16. Expert Opin Drug Saf. 2016. PMID: 26898906 Review.

Cite

Share

8

Cite

Share

What restricts the clinical use of nicotinic acid?

Kei A, Liberopoulos EN, Elisaf MS. Kei A, et al. Curr Vasc Pharmacol. 2011 Jul 1;9(4):521-30. doi: 10.2174/157016111796197215. Curr Vasc Pharmacol. 2011. PMID: 21314634 Review.

Cite

Share

9

Cite

Share

Statin use in prediabetic patients: rationale and results to date.

Kei A, Rizos EC, Elisaf M. Kei A, et al. Ther Adv Chronic Dis. 2015 Sep;6(5):246-51. doi: 10.1177/2040622315596118. Ther Adv Chronic Dis. 2015. PMID: 26336593 Free PMC article. Review.

Cite

Share

10

Cite

Share

Effects of PCSK9 Inhibitors on Other than Low-Density Lipoprotein Cholesterol Lipid Variables.

Filippatos TD, Kei A, Rizos CV, Elisaf MS. Filippatos TD, et al. Among authors: kei a. J Cardiovasc Pharmacol Ther. 2018 Jan;23(1):3-12. doi: 10.1177/1074248417724868. Epub 2017 Aug 22. J Cardiovasc Pharmacol Ther. 2018. PMID: 28826253 Review.

Cite

Share